GB1299198A - Pyrrolobenzodiazepinone derivatives - Google Patents

Pyrrolobenzodiazepinone derivatives

Info

Publication number
GB1299198A
GB1299198A GB62863/69A GB6286369A GB1299198A GB 1299198 A GB1299198 A GB 1299198A GB 62863/69 A GB62863/69 A GB 62863/69A GB 6286369 A GB6286369 A GB 6286369A GB 1299198 A GB1299198 A GB 1299198A
Authority
GB
United Kingdom
Prior art keywords
compound
formula
aryl
alkoxy
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB62863/69A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP44050780A external-priority patent/JPS4843755B1/ja
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of GB1299198A publication Critical patent/GB1299198A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1299198 Antibiotic pyrrolobenzodiazepinone derivatives FUJISAWA PHARMACEUTICAL CO Ltd 24 Dec 1969 [30 Dec 1968 26 June 1969] 62863/69 Heading C2A Novel pyrrolobenzodiazepinone derivatives having the Formula (I) wherein R 1 is H, C 1 -C 6 alkyl, C 1 -C 6 alkylcarbonyl, aryl-C 1 -C 6 alkylcarbonyl, or arylcarbonyl; Y is -N=CH- or -NH-CHR- and R is C 1 -C 6 alkoxy, aryl-C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, aryl-C 1 -C 6 alkylthio, or di(C 1 -C 6 alkyl)amino, are prepared from a new compound of unknown chemical structure obtained by aerobically cultivating Streptomyces achromogenes var. tomaymyceticus (ATCC 21353) by treating said compound as follows: (a) reacting with an alcohol of formula R<SP>1</SP>H to give a compound of Formula (A) wherein R<SP>1</SP> is C 1 to C 6 alkoxy; (b) dissolving the compound (A) in a non-alcoholic organic solvent to convert it into a compound of Formula (B) (c) reacting the compound (A) or the compound (B) with an acylating agent to form a compound of Formula (C) wherein R<SP>1</SP> 1 is C 1 -C 6 alkylcarbonyl, aryl- C 1 -C 6 alkylcarbonyl or arylcarbonyl, and Y is -N=CH- or -NH-CHR<SP>1</SP> and R<SP>1</SP> is as defined in (a) above; (d) reacting the compound (A) or the compound (B) with an alkylating agent to give a compound of Formula (D) wherein R<SP>11</SP> 1 is C 1 -C 6 alkyl and Y is -N = CH- or -NH-CHR<SP>1</SP> and R<SP>1</SP> is as defined in (a) above; (e) dissolving the compound (C) in which Y is -NH-CHR<SP>1</SP>- in a non-alcoholic organic solvent to convert it into a compound of Formula (E) wherein R<SP>1</SP> 1 is as defined in (c) above; (f) reacting the compound (B) or (E), or the compound (C) or (D) in which Y is -N=CH-, with an alcohol, thioalcohol or dialkylamine to give a compound of Formula (I) wherein R is C 1 -C 6 alkoxy, aryl-C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, aryl-C 1 -C 6 alkylthio, or di(C 1 -C 6 alkyl)- amino. The initial fermentation is carried out under conventional conditions for the culture of a Streptomycete. The said new compound may be subjected to the aforesaid treatment either in the fermentation broth (preferably filtered) or after isolation. Such isolation may be by extraction with a water-immiscible solvent (e.g. ethyl acetate or chloroform) or by adsorption on e.g. diatomaceous earth, activated carbon or alumina, silica gel or silicic acid, followed by elution with a polar organic solvent or aqueous such solvent. The compound may be purified by fractional chromatography and isolated by evaporation of the solvent or precipitation by adding a non-solvent. When an alcohol is used in the preparative procedure, the product is the alcohol-reaction compound (A) instead of the said new compound. The inventive compounds (I) variously have activity against gram-positive and gram-negative bacteria, phages, viruses and tumours. Pharmaceutical compositions having such activity comprise a compound of Formula I together with a physiologically acceptable carrier or diluent; they may be in forms suitable for injection or oral administration.
GB62863/69A 1968-12-30 1969-12-24 Pyrrolobenzodiazepinone derivatives Expired GB1299198A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8368 1968-12-30
JP44050780A JPS4843755B1 (en) 1969-06-26 1969-06-26

Publications (1)

Publication Number Publication Date
GB1299198A true GB1299198A (en) 1972-12-06

Family

ID=26332992

Family Applications (1)

Application Number Title Priority Date Filing Date
GB62863/69A Expired GB1299198A (en) 1968-12-30 1969-12-24 Pyrrolobenzodiazepinone derivatives

Country Status (6)

Country Link
ES (1) ES375013A1 (en)
FI (1) FI46259C (en)
GB (1) GB1299198A (en)
IE (1) IE33906B1 (en)
IL (1) IL33558A (en)
RO (1) RO55813A (en)

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101924A1 (en) * 1982-07-26 1984-03-07 Bristol-Myers Company Antitumor antibiotics
WO2000012508A2 (en) * 1998-08-27 2000-03-09 Spirogen Limited Pyrrolbenzodiazepines
US6608192B1 (en) 1998-08-27 2003-08-19 Spirogen Limited Collections of compounds
US6747144B1 (en) 1998-08-27 2004-06-08 Spirogen Limited Collections of compounds
US6909006B1 (en) 1999-08-27 2005-06-21 Spirogen Limited Cyclopropylindole derivatives
US7407951B2 (en) 2002-11-14 2008-08-05 Spirogen Limited Pyrrolobenzodiazepines
US7429658B2 (en) 2003-09-11 2008-09-30 Spirogen Limited Synthesis of protected pyrrolobenzodiazepines
US7528126B2 (en) 2004-03-09 2009-05-05 Spirogen Limited Pyrrolobenzodiazepines
US7557099B2 (en) 2004-03-01 2009-07-07 Spirogen Limited Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines
US7741319B2 (en) 2004-03-01 2010-06-22 Spirogen Limited 11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines
US8592576B2 (en) 2008-10-17 2013-11-26 Spirogen Sarl Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases
US8697688B2 (en) 2010-04-15 2014-04-15 Seattle Genetics Inc. Pyrrolobenzodiazepines used to treat proliferative diseases
US8829184B2 (en) 2010-04-15 2014-09-09 Spirogen Sarl Intermediates useful for the synthesis of pyrrolobenzodiazepines
US20140286970A1 (en) 2011-10-14 2014-09-25 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
US9102704B2 (en) 2011-10-14 2015-08-11 Spirogen Sarl Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
US9242013B2 (en) 2010-04-15 2016-01-26 Seattle Genetics Inc. Targeted pyrrolobenzodiazapine conjugates
US9388187B2 (en) 2011-10-14 2016-07-12 Medimmune Limited Pyrrolobenzodiazepines
US9387259B2 (en) 2011-10-14 2016-07-12 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
US9399073B2 (en) 2011-10-14 2016-07-26 Seattle Genetics, Inc. Pyrrolobenzodiazepines
US9399641B2 (en) 2011-09-20 2016-07-26 Medimmune Limited Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates
US9415117B2 (en) 2012-10-12 2016-08-16 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9745303B2 (en) 2012-10-12 2017-08-29 Medimmune Limited Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
US9919056B2 (en) 2012-10-12 2018-03-20 Adc Therapeutics S.A. Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9931415B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956298B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10335497B2 (en) 2012-10-12 2019-07-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10392393B2 (en) 2016-01-26 2019-08-27 Medimmune Limited Pyrrolobenzodiazepines
US10420777B2 (en) 2014-09-12 2019-09-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10543279B2 (en) 2016-04-29 2020-01-28 Medimmune Limited Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer
US10544223B2 (en) 2017-04-20 2020-01-28 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
US10695439B2 (en) 2016-02-10 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10736903B2 (en) 2012-10-12 2020-08-11 Medimmune Limited Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
US10751346B2 (en) 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US10799595B2 (en) 2016-10-14 2020-10-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11059893B2 (en) 2015-04-15 2021-07-13 Bergenbio Asa Humanized anti-AXL antibodies
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
US11352324B2 (en) 2018-03-01 2022-06-07 Medimmune Limited Methods
US11370801B2 (en) 2017-04-18 2022-06-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11517626B2 (en) 2016-02-10 2022-12-06 Medimmune Limited Pyrrolobenzodiazepine antibody conjugates
US11524969B2 (en) 2018-04-12 2022-12-13 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof as antitumour agents
US11612665B2 (en) 2017-02-08 2023-03-28 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US11649250B2 (en) 2017-08-18 2023-05-16 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11702473B2 (en) 2015-04-15 2023-07-18 Medimmune Limited Site-specific antibody-drug conjugates

Cited By (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101924A1 (en) * 1982-07-26 1984-03-07 Bristol-Myers Company Antitumor antibiotics
JP4824165B2 (en) * 1998-08-27 2011-11-30 スパイロジエン・リミテツド Pyrrolobenzodiazepines
US7067511B2 (en) 1998-08-27 2006-06-27 Spirogen Limited Pyrrolobenzodiazepines
EP1193270A2 (en) * 1998-08-27 2002-04-03 Spirogen Limited Pyrrolobenzodiazepines
EP1193270A3 (en) * 1998-08-27 2002-04-17 Spirogen Limited Pyrrolobenzodiazepines
US6608192B1 (en) 1998-08-27 2003-08-19 Spirogen Limited Collections of compounds
EP1413582A1 (en) * 1998-08-27 2004-04-28 Spirogen Limited Dimeric pyrrolobenzodiazepines
US6747144B1 (en) 1998-08-27 2004-06-08 Spirogen Limited Collections of compounds
US7704924B2 (en) 1998-08-27 2010-04-27 Spirogen Limited Library of compounds comprising pyrrolobenzodiazepine moieties
US7049311B1 (en) 1998-08-27 2006-05-23 Spirogen Limited Pyrrolbenzodiazepines
WO2000012508A2 (en) * 1998-08-27 2000-03-09 Spirogen Limited Pyrrolbenzodiazepines
US7265105B2 (en) 1998-08-27 2007-09-04 Spirogen Limited Pyrrolobenzodiazepines
WO2000012508A3 (en) * 1998-08-27 2000-09-21 Univ Portsmouth Pyrrolbenzodiazepines
US6909006B1 (en) 1999-08-27 2005-06-21 Spirogen Limited Cyclopropylindole derivatives
US7407951B2 (en) 2002-11-14 2008-08-05 Spirogen Limited Pyrrolobenzodiazepines
US7429658B2 (en) 2003-09-11 2008-09-30 Spirogen Limited Synthesis of protected pyrrolobenzodiazepines
US7557099B2 (en) 2004-03-01 2009-07-07 Spirogen Limited Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines
US7741319B2 (en) 2004-03-01 2010-06-22 Spirogen Limited 11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines
US7528126B2 (en) 2004-03-09 2009-05-05 Spirogen Limited Pyrrolobenzodiazepines
US8592576B2 (en) 2008-10-17 2013-11-26 Spirogen Sarl Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases
US9624227B2 (en) 2008-10-17 2017-04-18 Medimmune Limited Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases
US8940733B2 (en) 2008-10-17 2015-01-27 Spirogen Sarl Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases
US8697688B2 (en) 2010-04-15 2014-04-15 Seattle Genetics Inc. Pyrrolobenzodiazepines used to treat proliferative diseases
US9732084B2 (en) 2010-04-15 2017-08-15 Medimmune Limited Pyrrolobenzodiazepines used to treat proliferative diseases
US9592240B2 (en) 2010-04-15 2017-03-14 Seattle Genetics Inc. Targeted pyrrolobenzodiazapine conjugates
US9242013B2 (en) 2010-04-15 2016-01-26 Seattle Genetics Inc. Targeted pyrrolobenzodiazapine conjugates
US8829184B2 (en) 2010-04-15 2014-09-09 Spirogen Sarl Intermediates useful for the synthesis of pyrrolobenzodiazepines
US10561739B2 (en) 2010-04-15 2020-02-18 Seattle Genetics Inc. Targeted pyrrolobenzodiazapine conjugates
US9399641B2 (en) 2011-09-20 2016-07-26 Medimmune Limited Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates
US9399073B2 (en) 2011-10-14 2016-07-26 Seattle Genetics, Inc. Pyrrolobenzodiazepines
US9387259B2 (en) 2011-10-14 2016-07-12 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
US9526798B2 (en) 2011-10-14 2016-12-27 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
US9102704B2 (en) 2011-10-14 2015-08-11 Spirogen Sarl Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
US20140286970A1 (en) 2011-10-14 2014-09-25 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
US9707301B2 (en) 2011-10-14 2017-07-18 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
US9713647B2 (en) 2011-10-14 2017-07-25 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
US9388187B2 (en) 2011-10-14 2016-07-12 Medimmune Limited Pyrrolobenzodiazepines
US10328084B2 (en) 2011-10-14 2019-06-25 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
US10329352B2 (en) 2011-10-14 2019-06-25 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
US9931415B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10799596B2 (en) 2012-10-12 2020-10-13 Adc Therapeutics S.A. Pyrrolobenzodiazepine-antibody conjugates
US11690918B2 (en) 2012-10-12 2023-07-04 Medimmune Limited Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
US11701430B2 (en) 2012-10-12 2023-07-18 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US11771775B2 (en) 2012-10-12 2023-10-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10994023B2 (en) 2012-10-12 2021-05-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9919056B2 (en) 2012-10-12 2018-03-20 Adc Therapeutics S.A. Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
US9745303B2 (en) 2012-10-12 2017-08-29 Medimmune Limited Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
US10335497B2 (en) 2012-10-12 2019-07-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US11779650B2 (en) 2012-10-12 2023-10-10 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10780181B2 (en) 2012-10-12 2020-09-22 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US12121590B2 (en) 2012-10-12 2024-10-22 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9415117B2 (en) 2012-10-12 2016-08-16 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10646584B2 (en) 2012-10-12 2020-05-12 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10751346B2 (en) 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10722594B2 (en) 2012-10-12 2020-07-28 Adc Therapeutics S.A. Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
US10736903B2 (en) 2012-10-12 2020-08-11 Medimmune Limited Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US9956298B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10420777B2 (en) 2014-09-12 2019-09-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US11059893B2 (en) 2015-04-15 2021-07-13 Bergenbio Asa Humanized anti-AXL antibodies
US11702473B2 (en) 2015-04-15 2023-07-18 Medimmune Limited Site-specific antibody-drug conjugates
US10392393B2 (en) 2016-01-26 2019-08-27 Medimmune Limited Pyrrolobenzodiazepines
US10695439B2 (en) 2016-02-10 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11517626B2 (en) 2016-02-10 2022-12-06 Medimmune Limited Pyrrolobenzodiazepine antibody conjugates
US10543279B2 (en) 2016-04-29 2020-01-28 Medimmune Limited Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer
US10799595B2 (en) 2016-10-14 2020-10-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11612665B2 (en) 2017-02-08 2023-03-28 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US11813335B2 (en) 2017-02-08 2023-11-14 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US11370801B2 (en) 2017-04-18 2022-06-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
US10544223B2 (en) 2017-04-20 2020-01-28 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
US11938192B2 (en) 2017-06-14 2024-03-26 Medimmune Limited Dosage regimes for the administration of an anti-CD19 ADC
US11649250B2 (en) 2017-08-18 2023-05-16 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11352324B2 (en) 2018-03-01 2022-06-07 Medimmune Limited Methods
US11524969B2 (en) 2018-04-12 2022-12-13 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof as antitumour agents

Also Published As

Publication number Publication date
FI46259C (en) 1973-02-12
ES375013A1 (en) 1972-03-01
RO55813A (en) 1974-02-01
IE33906L (en) 1970-06-30
IL33558A (en) 1973-10-25
IE33906B1 (en) 1974-12-11
IL33558A0 (en) 1970-04-20
FI46259B (en) 1972-10-31

Similar Documents

Publication Publication Date Title
GB1299198A (en) Pyrrolobenzodiazepinone derivatives
Hanson et al. An antiphage agent isolated from Aspergillus sp
McInerney et al. Biologically active metabolites from Xenorhabdus spp., Part 2. Benzopyran-1-one derivatives with gastroprotective activity
Ohkuma et al. BBM-928, a new antitumor antibiotic complex I. Production, isolation, characterization and antitumor activity
Hochstein et al. 2-Acetyl-2-decarboxamidoöxytetracycline
Argoudelis et al. MICROBIAL TRANSFORMATION OF ANTIBIOTICS. III CONVERSION OF CLINDAMYCIN TO 1'-DEMETHYLCLINDAMYCIN AND CLINDAMYCIN SULFOXIDE BY STREPTOMYCES SPECIES
Argoudelis et al. Paulomycins A and B isolation and characterization
US4359583A (en) Antibiotics TM-531 B and TM-531 C
US4425430A (en) Process for production of antibiotics and novel antibiotics produced thereby
Brodasky et al. Steffimycin B, a new member of the steffimycin family: isolation and characterization
Keller-Juslen et al. Septamycin, a polyether antibiotic taxonomy, fermentation, isolation and characterization
Hamill et al. Macrocin, a new antibiotic, and lactenocin, an active degradation product
GB1303842A (en)
US4209511A (en) Aminoglycoside antibiotics and process for production thereof
Furumai et al. STUDIES ON THE BIOSYNTHESIS OF BASIC 16-MEMBERED MACROLIDE ANTIBIOTICS, PLATENOMYCINS. II PRODUCTION, ISOLATION AND STRUCTURES OF 3-O-PROPIONYL-5-OMYCAMINOSYL PLATENOLIDES I AND II, 9-DEHYDRO DEMYCAROSYL PLATENOMYCIN AND DEMYCAROSYL PLATENOMYCIN
IE37892B1 (en) Antibiotic a-2315 and process for preparation thereof
GB1226494A (en)
GB1292010A (en) A new antibiotic, its production and its use
AU652280B2 (en) Antibiotic LL-E19020 alpha1
Ando et al. A NEW ANTIBIOTIC, 1-(p-HYDROXYPHENYL)-2, 3-DIISOCYANO-4-(p-METHOXYPHENYL)-BUTA-1, 3-DIENE. I ISOLATION AND BIOLOGICAL PROPERTIES (STUDIES ON ANTIVIRAL AND ANTITUMOR ANTIBIOTICS. II)
US4003902A (en) Naphthyridinomycin antibiotics
IL42700A (en) Antibiotic g-52 and method for the production thereof
JPS6253157B2 (en)
Argoudelis et al. Directed biosynthesis of new celestosaminide-antibiotics by Streptomyces caelestis
SU1344248A3 (en) Method of producing macromide antibiotic

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PLNP Patent lapsed through nonpayment of renewal fees